Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGLTE2)

Drug Name

LY2922470 Drug Info

Synonyms

1423018-12-5; CHEMBL3955132; (S)-3-(4-((5-((8-Methoxy-3,4-dihydroquinolin-1(2H)-yl)methyl)thiophen-2-yl)methoxy)phenyl)hex-4-ynoic acid; LY-2922470; SCHEMBL14695980; BCP24962; BDBM50204012; HY-19835; CS-0016977; (3S)-3-[4-[[5-[(8-methoxy-3,4-dihydro-2H-quinolin-1-yl)methyl]thiophen-2-yl]methoxy]phenyl]hex-4-ynoic acid

Indication

Disease Entry	ICD 11	Status	REF
Type 2 diabetes	5A11	Phase 1	[1]

Cross-matching ID

PubChem CID: 71257551
CAS Number: CAS 1423018-12-5
TTD Drug ID: DMGLTE2

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Free fatty acid receptor 1 (GPR40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TAK-875	DMIM5AP	Type-2 diabetes	5A11	Phase 3	[3]
Fasiglifam hemihydrate	DMTGYSO	Type-2 diabetes	5A11	Phase 3	[4]
PBI-4050	DMPXK27	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[5]
P-1736	DMEYQPN	Diabetic complication	5A2Y	Phase 2	[6]
JTT-851	DMED5J6	Type-2 diabetes	5A11	Phase 2	[7]
SHR0534	DMGFTAI	Type 2 diabetes	5A11	Phase 1	[8]
LY-2881835	DM5EXJV	Type-2 diabetes	5A11	Phase 1	[7]
P11187	DMXZOI0	Type-2 diabetes	5A11	Phase 1	[7]
CPL207-280CA	DMFMGZR	Type 2 diabetes	5A11	Phase 1	[8]
CNX-011-67	DM1H8D6	Type 2 diabetes	5A11	Preclinical	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Free fatty acid receptor 1 (GPR40)	TTB8FUC	FFAR1_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01867216) A Study of Multiple Doses of LY2922470 in Participants With Diabetes. U.S. National Institutes of Health.
2	The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem. 2016 Dec 22;59(24):10891-10916.
3	Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab. 2015 Jul;17(7):675-81.
4	A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One. 2013 Oct 10;8(10):e76280.
5	Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663.
6	Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PLoS One. 2013 Oct 23;8(10):e77946.
7	Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137.
8	Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75.
9	CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. BMC Pharmacol Toxicol. 2014 Mar 25;15:19.